Sign inJoin waitlistJoin the waitlist

Tanios Bekaii-Saab

Division Chair, Division of Hematology and Medical Oncology, Department of Internal Medicine · Mayo Clinic College of Medicine and Science

Credentials: · · · ·

History

Division of Hematology and Medical Oncology Department · Mayo Clinic College of Medicine and Science
Present
Mayo Clinic College of Medicine and Science
Present
Mayo Clinic College of Medicine and Science
Present

Hematology-Oncology Tufts-New England Medical Center
1995–1998
Internal Medicine Indiana University Medical Center
1992–1995
American Univ of Beirut, Beirut, Lebanon
1988–1992

Research

Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
The Lancet · 2020 · 1,345 citations
Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma
Journal of Clinical Oncology · 2018 · Last of 29 authors · 536 citations
IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer
Gut · 2018 · 452 citations

Daniel Ahn
92 papers · 20 as a fellow
Mohamad Sonbol
68 papers · 6 as a fellow
Mitesh Borad
63 papers
Christina Wu
50 papers
OA
Oluseyi Abidoye
28 papers · 28 as a fellow
Amit Mahipal
22 papers
Kristen Ciombor
22 papers · 1 as a fellow
Thor Halfdanarson
22 papers
Mark Bloomston
21 papers
Robert McWilliams
21 papers
John Strickler
20 papers
Jason Starr
19 papers

Grants

Mayo Clinic Comprehensive Cancer Center Support Grant
National Cancer Institute · P30
Project lead · $524.6K · Mayo Clinic Rochester
1997–2025
Phase I Trial with Two HER-2 B Cell Epitope Vaccine in Patients with Solid Tumors
National Cancer Institute · R21
PI · $660K · Ohio State University
2009–2013

Clinical trials

BMS-986340 in Combination With Nivolumab, Gemcitabine and Nab-paclitaxel for the Treatment of Metastatic and Recurrent Pancreatic Adenocarcinoma
Principal investigator · Recruiting · Phase 2
Mayo Clinic
2025–2028
Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer
Principal investigator · Unknown · Phase 1, Phase 2
Academic and Community Cancer Research United
2018–2025
Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer
Principal investigator · Completed · Phase 2
Academic and Community Cancer Research United
2015–2023
Selumetinib and Akt Inhibitor MK-2206 in Treating Patients With Refractory or Advanced Gallbladder or Bile Duct Cancer That Cannot Be Removed By Surgery
Principal investigator · Withdrawn · Phase 2
National Cancer Institute (NCI)
2013